Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Sees Significant Growth in Short Interest

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 4,900 shares, an increase of 19.5% from the February 13th total of 4,100 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average trading volume of 33,200 shares, the days-to-cover ratio is presently 0.1 days.

Galmed Pharmaceuticals Price Performance

NASDAQ GLMD traded down $0.12 on Thursday, hitting $2.15. 73,356 shares of the company were exchanged, compared to its average volume of 892,847. Galmed Pharmaceuticals has a twelve month low of $1.67 and a twelve month high of $23.80. The firm has a market capitalization of $1.38 million, a P/E ratio of -0.13 and a beta of 0.72. The company’s 50 day moving average price is $2.51 and its 200-day moving average price is $3.43.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Galmed Pharmaceuticals in a research report on Thursday. They set a “sell” rating on the stock.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 76.14% of the stock is currently owned by institutional investors and hedge funds.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.